Table 2 Biochemical values and tumor characteristics in patients with PCC, SCS and NFA

Plasma Ad (pmol/mL)

0.13^¶ (0.05–0.29)

0.03 (0.02–0.03)

0.03^¶ (0.02–0.04)

0.080

0.044

NA (pmol/mL)

0.47^*¶ (0.28–3.10)

0.25^* (0.16–0.35)

0.28^¶ (0.16–0.40)

0.027

0.014

Urine Ad (μmol/day)

38.8^**¶ (10.6–98.6)

6.13^** (4.63–7.48)

7.2^¶ (4.35–8.88)

< 0.001

< 0.001

NA (μmol/day)

356^**¶¶ (166–1004)

99^** (85–114)

110^¶¶ (87–149)

< 0.001

< 0.001

MN (μmol/day)

0.74^**¶¶ (0.13–2.23)

0.09^** (0.08–0.09)

0.10^¶¶ (0.07–0.11)

< 0.001

< 0.001

NMN (μmol/day)

1.89^**¶¶ (1.20–3.87)

0.19^** (0.16–0.22)

0.19^¶¶ (0.16–0.30)

< 0.001

< 0.001

Plasma ACTH (pg/mL)

29.8 (22.8–40.3)

9.7 (8.9–14.1)

20.8 (13.1–38.8)

< 0.001

0.299

Serum F (μg/dL)

15.1 (12.3–16.9)

13.6 (12.2–16.4)

15.4 (12.7–17.0)

–

–

DHEA-S (μg/dL)

880 (559–1104)

371 (202–937)

840 (339–1191)

–

–

F after 1 mg DST (μg/dL)

1.5 (1.2–1.7)

6.1 (4.0–10.6)

1.4 (1.3–2.3)

< 0.001

1.000

Tumor size (cm)

4.0^¶¶ (2.5–7.8)

2.7 (2.2–3.4)

2.4^¶¶ (1.5–3.0)

0.204

0.001

CT value (HU)

36^**¶¶ (27–42)

15^** (6–18)

19^¶¶ (4–27)

< 0.001

0.003